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ABSTRACT 
EFFECTS OF 670 NM AND 830 NM LIGHT ON THE IMMUNE 
RESPONSE TO BORRELIA BURGDORFERI 
 
by 
Felice Chen 
 
The University of Wisconsin-Milwaukee, 2015 
Under the Supervision of Dean T. Nardelli, Ph.D. and Janis T. Eells, Ph.D. 
 
 
Lyme arthritis is a debilitating joint disorder that arises from Lyme disease, 
which is a result of infection by the spirochete Borrelia burgdorferi. 
Antibiotics are the traditional treatment for Lyme disease, but chronic 
arthritis may persist in some patients despite antibiotic treatment. 
Therefore, other forms of treatment for Lyme arthritis are needed. 
Photobiomodulation (PBM) using red or near-infrared light, with 
wavelengths between 630 nm and 900 nm, has been found to be 
beneficial in alleviating inflammatory symptoms of many disorders. The 
purpose of this thesis was to determine whether photobiomodulation using 
either 670 nm or 830 nm light would help alleviate inflammation in a 
murine Lyme arthritis model. The central hypothesis for this study was that 
PBM, using 670 nm or 830 nm light, will decrease inflammation in Lyme 
arthritis. Two specific aims were pursued to test this hypothesis. The first 
aim was to determine the effect that 670 nm and 830 nm light had on paw 
swelling and pro-inflammatory cytokine levels in B. burgdorferi-infected 
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mice. The working hypothesis for this specific aim was that 670 nm and 
830 nm light would ameliorate swelling and reduce interleukin-17 (IL-17) 
and interferon-gamma (IFN-γ) production in B. burgdorferi-infected mice. 
The second aim was to determine the effect of 670 nm or 830 nm light had 
on production of borreliacidal antibodies in infected mice. The working 
hypothesis for this specific aim was that neither 670 nm nor 830 nm light 
would affect borreliacidal antibody production in B. burgdorferi-infected 
mice. 
 
Wild-type or interleukin-10-deficient C57BL/6 mice were infected with B. 
burgdorferi and treated with either 670 nm light or 830 nm light for six or 
seven consecutive days. Infected paws were then measured for changes 
in paw swelling, and IL-17 and IFN-γ production by spleen cells were 
determined. Sera were used to determine borreliacidal antibody titers.  
Our hypothesis was partially supported, in that PBM using 670 nm light 
was capable of significantly decreasing IFN-γ production. Surprisingly, 670 
nm light also increased the borreliacidal antibody titer in a model of 
dysregulated disease. However, it was unable to decrease the paw 
swelling exhibited in murine Lyme arthritis. Our hypothesis was not 
supported by the use of 830 nm light. Treatment with 830 nm light did not 
significantly affect paw swelling, and it significantly increased IL-17 
production and reduced borreliacidal antibody titers in the model of 
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dysregulated Lyme arthritis. Our results indicate that different wavelengths 
may possess varying effects on inflammation in Lyme arthritis.  
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CHAPTER 1: INTRODUCTION 
 
I. Lyme Disease 
 
1. Introduction 
 
Lyme disease is a tick-borne disorder caused by infection with the 
spirochete Borrelia burgdorferi after bites from infected ticks of the Ixodes 
genus (Bhate and Schwartz, 2010). The disease is endemic to the 
Northeast, upper Midwest, and far West regions of the United States, as 
well as to parts of Europe (Hu, 2005; Nardelli et al., 2008a). The deer tick 
I. scapularis serves as a primary vector for B. burgdorferi (Steere et al., 
2004), and reservoirs for Ixodes ticks vary from region to region. A 
common reservoir for I. scapularis is the white-footed mouse (Bhate and 
Schwartz, 2010), although other small mammals and the white-tailed deer 
also serve as reservoirs for the species (Magnarelli et al., 1991). 
Transmission is highest during the late spring to early summer months 
due to the high feeding rate exhibited by ticks at the nymph stage of 
development (Steere et al., 2004). A recent report by the Centers for 
Disease Control and Prevention indicated that there are about 300,000 
cases of Lyme disease per year in the U.S., which is ten times higher than 
has been reported in the past (Centers for Disease Control and 
Prevention, 2013a). 
  
B. burgdorferi was first isolated from Ixodes ticks in 1982 (Burgdorfer et 
al., 1982). It is a Gram-negative, microaerophilic, spiral-shaped organism 
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that averages about 4 to 30 μm in length. B. burgdorferi possesses 
various lipoproteins that aid in its transmission by the tick vector and 
promote infection in the human host. Outer surface protein (Osp) A binds 
to a tick receptor for Osp A, TROPSA, in the tick midgut (Pal et al., 2004), 
facilitating its anchorage within the tick between blood meals. During 
feeding, expression of OspA is downregulated, allowing for movement of 
B. burgdorferi into the host. At the same time, OspC is upregulated. This 
protein, which is required for infection, binds to tick salivary protein 
Salp15, which increases infectivity in the host (Ramamoorthi et al., 2005). 
Expression of other proteins, such as variable surface antigen (VlsE) and 
decorin-binding protein (Dbp) A (Guo et al., 1998; Indest et al., 2001; 
Bhate and Schwartz, 2010), facilitate spirochete transmission and 
dissemination within the host. VlsE was found to be involved in promoting 
antigenic variation for the spirochete through random recombination at the 
vls locus (McDowell et al., 2002), while DbpA binds to collagen-rich sites 
in the host and aid spirochete attachment (Guo et al., 1998). While in the 
host, B. burgdorferi induces inflammatory responses that account for the 
various symptoms of Lyme disease.  
 
The interaction of OspC with Salp15 illustrates the contribution of tick 
salivary products in aiding infection with B. burgdorferi. Salp15-bound B. 
burgdorferi were found to be resistant to antibody-mediated killing, 
indicating a protective function of tick saliva for the spirochete (Hovius et 
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al., 2008). Tick saliva is known to contain other proteins that facilitate 
spirochete transmission to humans. Immunosuppressive proteins such as 
B-cell inhibitory protein and sialostatin L have been found in tick saliva, as 
well (Hannier et al., 2004; Kotsyfakis et al., 2006; Horka et al., 2012), and 
appear to help reduce host immunological barriers during transmission. 
 
2. Clinical Manifestations of Lyme Disease   
Clinical manifestations of Lyme disease typically consist of three stages. 
In the first stage, erythema migrans (EM), a rash that is occasionally 
characterized by concentric circles surrounding a central clearing, can 
develop from the original site of the tick bite (Centers for Disease Control 
and Prevention, 2013b). EM is exhibited by about 50% of adults and 90% 
of children infected with B. burgdorferi, and it is considered a hallmark sign 
of Lyme disease in endemic areas (Bhate and Schwartz, 2010). In 
addition to EM rashes, typical symptoms during the first stage include pain 
in the joints, muscles, and bones, fever, malaise, and enlarged lymph 
nodes (Biesiada et al., 2012; Bhate and Schwartz, 2010).  
 
Over the days and weeks following untreated infection, the spirochetes 
disseminate to various regions of the body, and may cause the 
development of multiple EM rashes, neck stiffness, headaches, 
asymmetrical joint inflammation, and, in rare cases, atrioventricular 
blockage and carditis (Hu, 2005; Bhate and Schwartz, 2010). An 
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asymptomatic period may occur after the second stage, followed by the 
third stage, which may occur months to years after initial infection. In the 
final stage of untreated infection, EM rashes are rare, and manifestations 
may include memory impairment and cardiac disorders. In addition, 
persistent joint inflammation, known as Lyme arthritis, may develop (Bhate 
and Schwartz, 2010).  
 
3. Lyme Arthritis  
Lyme arthritis is a chronic, debilitating complication of later-stage B. 
burgdorferi infection that results from persistent joint inflammation. Lyme 
arthritis is characterized by infiltration of the synovium by inflammatory 
cells and, in its most severe forms, pannus formation, gradual degradation 
of the cartilage, and bone erosion. These immune events cause recurrent 
pain and inflammation of the joints and may hinder normal movement. 
Lyme arthritis manifests in about 50% of untreated Lyme disease patients 
(Centers for Disease Control and Prevention, 2013b). Antibiotics, including 
ceftriaxone and doxycycline, are commonly used to cure infection and 
alleviate symptoms of Lyme arthritis, and have proven to be effective for 
most patients (Dattwyler et al., 1988; Steere et al., 1994). However, 
instances of chronic arthritic symptoms may exist even after antibiotic 
treatment in some genetically predisposed patients. This condition, 
commonly called antibiotic-refractory Lyme arthritis, occurs in about 10% 
of Lyme arthritis patients (Steere and Angelis, 2006; Wormser et al., 
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2012). These symptoms can remain even after B. burgdorferi levels 
become undetectable (Carlson et al., 1999). In addition, Li et al. (2011) 
demonstrated that synovial tissues of patients experiencing relapses in 
arthritic symptoms, after an antibiotic course, exhibited negative 
polymerase chain reaction results for presence of B. burgdorferi. These 
studies indicate that infection with viable B. burgdorferi may not be the 
sole cause of arthritic inflammation in some patients. 
 
4. Theories on Antibiotic-Refractory Lyme Arthritis 
Currently, it is unclear why some patients develop antibiotic-refractory 
Lyme arthritis. Several explanations may account for this occurrence. One 
possible explanation is that antibiotic-refractory patients may be 
genetically predisposed to experiencing prolonged inflammatory 
symptoms after infection (Steere and Glickstein, 2004). A study conducted 
by Steere et al. (1990) demonstrated that patients who experienced 
antibiotic-refractory Lyme arthritis possessed a significantly greater 
frequency of either human leukocyte antigen (HLA)-DR4 or HLA-DR2 
major histocompatibility complex alleles. DR4+ mice lacking CD28 and 
MHC II were also shown to exhibit a higher percentage of arthritis 
development and possess persistent paw inflammation even after 
antibiotic administration, as opposed to mice only deficient in CD28 
(Iliopoulou et al., 2008). Lymph node cells of DR4 transgenic mice also 
produced significantly greater interferon-γ (IFN-γ) levels than those of 
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DR11 transgenic mice, which are resistant to antibiotic-refractory arthritis 
(Iliopoulou et al., 2009). Collectively, these studies support the hypothesis 
that presence of HLA-DR4 alleles may contribute to the genetic 
predisposition to antibiotic-refractory Lyme arthritis in some patients.  
 
Another possible explanation for antibiotic-refractory Lyme arthritis 
involves possible dysregulation of the immune system (Steere and 
Glickstein, 2004). In this case, it is hypothesized that the host immune 
response is unable to control the pro-inflammatory responses induced by 
initial infection. Therefore, pro-inflammatory mediators are persistently 
elicited and may result in chronic joint inflammation (Steere and Glickstein, 
2004).  
 
Another hypothesis is that the occurrence of persistent inflammation in 
Lyme arthritis may be due to a theory known as the “amber hypothesis”. 
This theory suggests that persistent, antibiotic-resistant arthritis may be 
the result of the presence of non-viable B. burgdorferi or its fragments 
retained in, or dislodged from, tissue within the joints (Wormser et al., 
2012). The remnants of spirochetal antigens may trigger inflammatory 
responses by the host and result in the persistent bouts of inflammation in 
Lyme arthritis. Indeed, administration of borrelial antigens into the joint 
spaces of rats induced mild arthritis and resulted in the antigens being 
embedded in the synovial membrane of joints (Gondolf et al., 1994). In 
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addition, Petzke et al. (2009) showed that both viable and dead 
spirochetes induced similar inflammatory transcriptional profiles in the 
peripheral blood mononuclear cells (PBMCs) of humans. These findings 
suggest that viable, whole spirochetes may not be required to induce an 
immune response. 
 
5. Mouse Models for Lyme Arthritis 
Animal models, including rhesus monkeys, rabbits, dogs, and various 
rodents, have been used to study Lyme arthritis progression (Barthold et 
al., 2010). Mice are the most commonly used models for this disease. 
C3H mice are particularly susceptible to developing severe arthritis once 
infected with B. burgdorferi and are useful for analyzing the immune 
events following infection (Ma et al., 1998). BALB/c mice are typically 
arthritis-resistant, but may develop mild to severe arthritis when 
administered high doses of spirochete (Ma et al., 1998). C57BL/6 mice are 
arthritis-resistant, exhibiting mild inflammation after infection (Barthold et 
al., 1990). However, interleukin-10 (IL-10)-deficient mice in a C57BL/6 
background have been shown to develop severe arthritis upon infection 
(Brown et al., 1999). The use of these, and other, animal models of Lyme 
arthritis are key to understanding the wide variety of immune responses 
that occur in humans. 
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6. Innate Response to B. burgdorferi-Infection  
Toll-like receptors (TLRs) play a crucial role in the initial recognition of, 
and subsequent responses to, the presence of a pathogen. Several TLRs, 
such as TLR2, 5, 7, and 9, have been implicated in the initial responses to 
B. burgdorferi. In particular, expression of TLR2 was found to be 
associated with the response to OspA, which triggers pro-inflammatory 
responses via the NF-κB pathway (Hirschfeld et al., 1999). Hirschfeld et 
al. (1999) discovered that transfection of TLR2 into TLR2-negative U373 
cell lines, which do not respond to OspA, led to responsiveness to the 
lipoprotein, and that presence of CD14, a monocyte differentiation marker, 
was important for this responsiveness. This finding supports evidence of a 
vital role for TLR2 in the initial recognition of OspA. In addition, the joints 
of Borrelia-infected TLR2-deficient mice have been shown to possess a 
greater spirochete load and exhibit more swelling than their wild-type 
counterparts (Wooten et al., 2002), suggesting that activation of TLR2 
contributes significantly to pathogen clearance.  
 
Myeloid differentiation antigen 88 (MyD88), an adaptor molecule for TLR 
signaling and activation of NF-κB, has been found to be important in the 
innate response to B. burgdorferi. Spirochete clearance in B. burgdorferi-
infected, MyD88-deficient mice was less efficient than in their wild-type 
counterparts (Liu et al., 2004). Macrophages of MyD88-deficient mice also 
degraded B. burgdorferi at a slower rate and in an incomplete fashion 
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compared to those of wild type mice (Liu et al., 2004). These results 
demonstrate the role of both TLR2 and MyD88 in effective spirochete 
clearance. However, as disease due to B. burgdorferi infection may still 
occur in TLR2- or MyD88-deficient mice, other inflammatory pathways are 
triggered in response to infection. 
 
TLR5, TLR7, and TLR9 were also demonstrated to be involved in the 
initial recognition of B. burgdorferi antigens. The silencing of TLR5 mRNA 
resulted in decreased gene expression of pro-inflammatory mediators 
such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and 
interleukin-6 (IL-6) in B. burgdorferi-stimulated macrophages (Shin et al., 
2008), signifying that TLR5 may have a role in inflammation upon 
stimulation by B. burgdorferi. In addition, inhibition of TLR7 and TLR9 
signaling led to a decrease in interferon-α production in human peripheral 
blood mononuclear cells (Petzke et al., 2009).  
 
Various innate cells of the human host, such as macrophages, dendritic 
cells, natural killer (NK) cells, and neutrophils, are elicited upon infection 
with B. burgdorferi. Dendritic cells (DCs) and macrophages play a role in 
the activation of the adaptive immune response in Lyme arthritis. It was 
demonstrated, in an adoptive transfer study, that DCs exposed to B. 
burgdorferi are capable of generating a protective response in naïve 
BALB/c and C3H mice by stimulating the production of antibodies against 
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OspA (Mbow et al., 1997). Phagocytosis of B. burgdorferi by macrophages 
is also crucial in eliminating the presence of the spirochete during infection 
(Montgomery and Malawista, 1996). It was found by Ma et al. (1994) that 
OspA is capable of inducing the release of a variety of pro-inflammatory 
mediators, including interleukins-1 and- 12, as well as interferon-β, from 
bone marrow-derived macrophages of C3H mice. Macrophage stimulation 
by OspA also subsequently induced production of IFN-γ by NK cells and T 
cells in C3H mice (Ma et al., 1994). In addition, both OspA and OspB were 
found to elicit the production of nitric oxide (NO) from the macrophages of 
C3H mice (Ma et al., 1994), which is a crucial component in pathogen 
elimination by macrophages (Green et al., 1990). Both macrophages and 
DCs are important in eliciting T cell responses in the presence of B. 
burgdorferi, with macrophages capable of inducing both naïve and mature 
T cell proliferation after B. burgdorferi infection (Altenschmidt et al., 1996). 
 
Brown and Reiner (1998) demonstrated that NK cells produced more IFN-
γ in the lymph nodes of B. burgdorferi-infected, arthritis-susceptible, 
C3H/HeJ mice than those of arthritis-resistant DBA mice. This suggests 
that NK cell functions may contribute to the severity of inflammation in 
Lyme arthritis. In addition, the presence of neutrophils is also important in 
the control of B. burgdorferi. For example, a chemokine-induced presence 
of neutrophils led to a more effective control in the number of B. 
burgdorferi organisms present in the heart, skin, and joints of severe 
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combined immunodeficient (SCID) mice of a BALB/c background (Xu et 
al., 2007). In addition, it was found by Guo et al. (2009) that tick salivary 
proteins decreased neutrophil function by inhibition of integrins and 
reduction of superoxide production, which may explain the disappearance 
of neutrophil aggregates in EM rashes (Xu et al., 2007). Finally, Codolo et 
al. (2013) showed that neutrophils are recruited to the site of infection by 
the B. burgdorferi antigen neutrophil-activating protein A (NapA) and that 
these cells release T cell attractants to induce T cell-mediated immune 
responses. These studies demonstrate that neutrophils act as a crucial 
initial defense against the spirochete, while supporting additional 
inflammatory cells during infection. 
 
7. Involvement of IFN-γ and IL-17 in Lyme Arthritis 
Studies have demonstrated that T helper type 1 (Th1) cells and the 
cytokines they secrete, particularly IFN-γ, are involved throughout the 
course of inflammation in Lyme arthritis. Cloned T cells obtained from 
synovial fluid and peripheral blood mononuclear cells of patients with 
chronic Lyme arthritis displayed a Th1 cytokine pattern when stimulated 
with B. burgdorferi antigens in vitro (Yssel et al., 1991). Specifically, OspA 
was shown to stimulate an IFN-γ response (Ma et al., 1994). It was also 
found that cells of synovial fluid from Lyme arthritis patients produced a 
high amount of IFN-γ when stimulated by B. burgdorferi (Yin et al., 1997). 
In further support of the role of IFN-γ in Lyme arthritis, it was found that 
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lymph nodes of the arthritis-susceptible C3H mouse produced a 
significantly greater amount of the cytokine upon stimulation with B. 
burgdorferi antigens than those of arthritis-resistant BALB/c mice (Keane 
Myers and Nickell, 1995). Another study demonstrated that a greater 
severity of Lyme arthritis in patients is directly correlated with a greater 
ratio of Th1 to Th2 cells, and that these Th1 cells are specific for OspA 
antigens and localized in the inflamed joints (Gross et al., 1998). In 
addition, C3H mice, which are prone to arthritis after infection with B. 
burgdorferi, display a Th1 profile during infection, whereas BALB/c mice, 
which experience milder arthritis, exhibit a Th2 profile during infection 
(Matyniak and Reiner, 1995). Moreover, patients unresponsive to 
antibiotics produced higher levels IFN-γ than responsive patients (Shin et 
al., 2007). Finally, it was demonstrated by Codolo et al. (2013) that the T 
cells in synovial fluid of Lyme arthritis patients produced IFN-γ when 
stimulated by NapA. These studies collectively suggest that IFN-γ strongly 
contributes to ongoing inflammation of the joints in Lyme arthritis. 
 
However, there are some indications that IFN-γ is not solely responsible 
for the induction of Lyme arthritis. Brown and Reiner (1999) demonstrated 
that C3H mice deficient in IFN-γ exhibited a greater severity of arthritis 
compared to wild-type C3H mice, indicating that the presence of IFN-γ 
may not be required for arthritis development. In a different model of 
disease, Christopherson et al. (2003) demonstrated that persistent arthritis 
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was still exhibited by IFN-γ-deficient mice. Glickstein et al. (2001) further 
showed that IFN-γ-receptor-deficient mice controlled infection in a manner 
comparable to wild type control mice. These studies provide evidence that 
Lyme arthritis may not be mediated solely by IFN-γ activity, and that other 
cytokines may also contribute to inflammation.  
 
Type 17 helper T (Th17) cells are another inflammatory subset of T helper 
cells. Transforming growth factor-β (TGF-β) and IL-6 are both key players 
in the differentiation of Th17 cells, and both are required for the 
differentiation of naïve T cells into IL-17-producing T cells (Veldhoen et al., 
2006). Th17 cells secrete the pro-inflammatory cytokine interleukin-17 (IL-
17), along with other pro-inflammatory mediators, such as TNF-α and 
granulocyte macrophage colony-stimulating factor (GM-CSF). 
Recombinant human IL-17 was found to stimulate the release of other pro-
inflammatory cytokines, such as IL-1β and TNF-α, in macrophages 
(Jovanovic et al., 1998). IL-17 also induces a variety of chemoattractants, 
such as monocyte chemoattractant protein 1 (Shahrara et al., 2010). IL-17 
has also been shown to induce the expression of intracellular adhesion 
molecule-1 in human fibroblasts (Yao et al., 1995).  
 
The involvement of IL-17 has been documented in various arthropathies. 
For example, IL-17 is involved in cartilage and joint destruction in a 
collagen-induced arthritis model (Lubberts et al., 2001). In addition, high 
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levels of IL-17 were found in the synovial fluid of patients with rheumatoid 
arthritis (Ziolkowska et al., 2000), and in the sera of patients with early 
inflammatory arthritis (Gullick et al., 2013). Fluid in the joints of juvenile 
idiopathic arthritis patients was also shown to be dominated by Th17 cells 
(Nistala et al., 2008). IL-17 also was shown to be associated with 
increased NO levels in human cartilage (Attur et al., 1997), which is a 
possible mode of cartilage destruction. Collectively, these findings suggest 
a role for IL-17 in enhancing inflammation and exacerbating arthritis.  
 
Indeed, there are a growing number of studies which demonstrate the 
contribution of Th17 cells and IL-17 to joint inflammation in Lyme arthritis. 
It was first shown by Infante-Duarte et al. (2000) that B. burgdorferi 
antigens are capable of stimulating IL-17 production by T cells of synovial 
fluid in humans and by spleen cells of mice. It was also found, using a 
model of Borrelia-induced arthritis in IFN-γ-deficient C57BL/6 mice, that 
neutralization of IL-17 or its receptor reduced paw swelling and 
histopathologic changes of the joint (Burchill et al., 2003). In addition, it 
was found that inhibition of IL-17 was associated with an increased 
presence of local T cells with immunoregulatory function (Nardelli et al., 
2004). This study suggested that a possible factor for the pro-inflammatory 
conditions elicited during Lyme arthritis is insufficient regulatory T cell 
activity. Furthermore, NapA has also been found to stimulate the 
production of IL-17, IL-1β, IL-6, interleukin-23 (IL-23), and TGF-β (Codolo 
15 
 
 
et al., 2008). NapA also acts as a chemoattractant for IFN-γ- and IL-17-
producing T cells in the synovial fluid of Lyme arthritis patients (Codolo et 
al., 2013).  In addition, spleen cells of infected, arthritis-resistant C57BL/6 
mice produced less IL-17 compared to an IL-10-deficient strain of the 
same genotype, which is known to develop arthritis (Hansen et al., 2013). 
This finding further demonstrates the inflammatory role of IL-17 in Lyme 
arthritis and provides evidence of a possible regulator of IL-17 after 
infection with B. burgdorferi.   
 
Finally, other cytokines involved in the production of IL-17 have been 
shown to be involved in the development of Lyme arthritis. The presence 
of IL-23, a promoter of Th17-derived IL-17 (Langrish et al., 2005), was 
found to be required for arthritis development in vaccinated C57BL/6 mice 
infected with B. burgdorferi (Kotloski et al., 2008). In addition, Codolo et al. 
(2008) found that IL-23 production by monocytes and neutrophils was 
stimulated by NapA. Moreover, increased serum IL-23 levels were found 
in patients who experienced antibiotic-refractory Lyme disease symptoms 
(Strle et al., 2013). Taken together, this information suggests that IL-23 
may contribute to the pathogenesis of Lyme arthritis inflammation. In 
addition, TGF-β and IL-6 are involved in the development of Th17 cells. 
The presence of both IL-6 and TGF-β are required for arthritis 
development in B. burgdorferi-vaccinated and -challenged C57BL/6 mice 
(Nardelli et al., 2008b). Since the pro-inflammatory inducers of IL-17 are 
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required for increasing the severity of arthritis, these findings suggest that 
IL-17 plays a significant role in promoting inflammation in Lyme arthritis.  
 
Identifying inflammatory mediators of Lyme arthritis allows for better 
understanding of targets for treatments for the disease. The use of 
antibiotics to treat Lyme disease and arthritis, while effective for most 
patients, is not effective for some. In addition, prolonged use of antibiotics 
may cause various harmful effects. Therefore, alternative therapies may 
need to be developed to alleviate the symptoms of Lyme arthritis. 
Phototherapy may be one such alternative, since it is non-invasive and 
has been shown to reduce inflammation in other disease models. 
 
II. Photobiomodulation 
1. Background 
Exposure to light from the far-red to near-infrared (NIR) regions (630—
900nm) of the electromagnetic spectrum has been shown to modulate 
various cellular and molecular functions (Karu, 2003). This phenomenon 
has been termed “photobiomodulation” (PBM). PBM has been applied 
clinically in the treatment of soft tissue injuries and acceleration of wound 
healing for more than 40 years (Chung et al., 2012). Recent studies have 
demonstrated that FR/NIR photons penetrate diseased tissues including 
muscle, spinal cord and brain. PBM is an increasingly studied form of 
therapy due to its documented benefits in other disorders, including retinal 
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degeneration and neural inflammation (Eells et al., 2003; Desmet et al., 
2006; Muili et al., 2012). Two types of light sources are employed in PBM: 
low-power lasers and light-emitting diode (LED) arrays. Low-power lasers 
were the first type of light source used in PBM. However, certain 
limitations, including potential damage induced by heat production and 
inability to treat large wound areas, increased the use of LED arrays 
(Whelan et al., 2001). LEDs can be produced to emit different 
wavelengths of light and can be manufactured in the form of arrays, 
allowing larger surface areas to be treated. There is also little risk of tissue 
damage from FR/NIR LED units. Moreover, the FDA has approved 
FR/NIR LED arrays for applications in soft-tissue injury and inflammation 
in humans (Whelan et al., 2001).  
One reason PBM continues to possess a low profile in medicine is 
because there is an incomplete understanding of its mechanism(s) of 
action. PBM obeys the fundamental laws of photochemistry: 1) FR or NIR 
light must be absorbed by a photoacceptor molecule or molecules for 
PBM to occur, 2) only one molecule is activated per photon, 3) 
effectiveness depends on the degree of absorbance associated with 
various wavelengths, as demonstrated by the absorption spectrum of the 
photoacceptor molecule, and finally, 4) effectiveness also depends on the 
degree to which a particular wavelength induces biochemical changes, as 
defined by the action spectrum, a plot which illustrates the ability of the 
various wavelengths of light to induce biochemical or physiological 
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changes. The comparison between the action spectrum and absorption 
spectrum indicate which wavelengths are the most effective in stimulating 
cellular activity (Karu, 1989). Studies have also shown that PBM is more 
effective at inducing biochemical changes in cells or tissues which have 
sustained some form of injury or are dysfunctional (Karu, 1989). Moreover, 
it has been found that the absorption spectrum of cytochrome c oxidase 
and the action spectrum of FR/NIR light correspond with each other 
(Wong-Riley et al., 2005). Light at wavelengths between 600 nm—700 nm 
are generally used to treat more superficial wounds, while wavelengths 
between 780—950 nm have been shown to be more effective in treating 
deeper wounds (Chung et al., 2012). Commonly employed wavelengths 
for PBM studies include 670 nm in the far-red region of the spectrum and 
830 nm in the NIR region of the spectrum (Fitzgerald et al., 2013).  
 
Other key factors limiting the use of PBM in medicine are the selection of 
wavelengths, the most efficacious dose of light, and the dosing schedule. 
Many different wavelengths and dosage regimens have been applied with 
varying success in the treatment of wound and soft tissue injuries 
(Fitzgerald et al., 2013). Although the action spectrum and absorption 
spectrum have established certain wavelengths that are associated with 
greater biochemical changes, factors such as the fluence, intensity of the 
light, the duration of treatment, and area of the wound being treated are 
also crucial for the success of PBM (Chung et al., 2012). The dosage, or 
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fluence (J/cm2), is defined as the number of photons applied per square 
centimeter of the area treated. It is a product of the light intensity 
(mW/cm2) and duration of treatment (seconds). Fluences employed in 
PBM have been reported to be as low as 0.5 J/cm2 or as high as 268 
J/cm2. Similarly, the intensity of light used in studies ranges from  2 
mW/cm2 to 2230 mW/cm2 (Fitzgerald et al., 2013). In addition, variability in 
other treatment parameters, including total number of treatments and 
number of treatments per day, have been reported. For acceptance into 
mainstream medicine, reproducible dosage regimens need to be 
established for different disease states.  
 
2. Mechanism(s) of Action of Photobiomodulation  
Considerable experimental evidence indicates that cytochrome c oxidase 
is a primary photoacceptor molecule in photobiomodulation mediated by 
FR/NIR light (Wong-Riley et al., 2005). Cytochrome c oxidase (CcO) is the 
terminal electron acceptor in the mitochondrial electron transport chain. 
Importantly, CcO plays a key role in mitochondrial function and in 
retrograde signaling from the mitochondrion to the nucleus. PBM using 
FR/NIR light can induce a variety of biochemical signaling pathways after 
light absorption (Karu et al., 2003). Cellular events including up-regulation 
of the synthesis of anti-inflammatory cytokines may occur, along with 
simultaneous downregulation of pro-inflammatory cytokines.  
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One proposal for the mechanism of action of PBM is the displacement of 
NO from CcO, resulting in both increased ATP synthesis and activation of 
transcription factors (Karu, 2010). When NO is bound to CcO, it prevents 
oxygen from binding to the photoacceptor, thereby inhibiting cellular 
respiration and ATP production. The interaction of FR/NIR light with CcO 
causes a conformational change in CcO, resulting in the release of NO 
(Prindeze et al., 2012). This release allows oxygen to take the place of 
NO, and triggers cellular respiration and ATP production. The increase in 
ATP production ultimately enhances the potential for cellular repair (Karu, 
2014). The replacement of NO with oxygen binding to CcO leads to a 
switch in redox states for the photoacceptor, and a subsequent increase in 
proton transport, resulting in an increase in mitochondrial membrane 
potential and, thus, increased ATP synthesis (Prindeze et al., 2012).  
 
The NO displaced has been postulated to diffuse into the cytosol and 
activate transcription factors resulting in enhanced production of 
cytoprotective proteins (Karu et al., 2014), as light treatment has been 
found to change chromatin structure in human lymphocytes, which was 
indicative of a possible increase in cellular proliferation (Fedoseyeva et al., 
1988). Additionally, studies have shown an increased release of 
antioxidants, such as manganese superoxide dismutase (MnSOD) and 
glutathione, after light treatment (Hodgson et al., 2011; Kirk et al., 2013), 
which indicates a possible cytoprotective mechanism induced by PBM. 
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Since NO possesses a variety of immunoregulatory functions (Bogdan, 
2001), the NO displaced by cytochrome c oxidase may exert an anti-
inflammatory effect in cells. NO is produced by a variety of immune cells, 
including macrophages and neutrophils, as well as endothelial cells, 
epithelial cells, fibroblasts, keratinocytes, and Schwann cells (Bogdan, 
2001). It is responsible for regulation of a wide variety of immunological 
activities, including T and B cell inhibition, regulation and production of 
various cytokines and chemokines, and regulation of transcription factors 
such as NF-κB, which is responsible for inducing genes involved in pro-
inflammatory responses (Connelly et al., 2001; Prindeze et al., 2012). 
Therefore, the release of NO from CcO after FR/NIR light absorption may 
result in increased NO signaling to regulate immune events. 
 
3. Photobiomodulation Effects on Various Arthropathies 
Despite the uncertainty about the mechanisms of PBM and the 
parameters that make it successful, studies have documented the 
increased cellular regeneration and anti-inflammatory effects of PBM in 
various types of arthritis. Whelan et al. (2001) demonstrated that LED 
treatment of various cell lines using 670 nm and 880 nm, at a dosage of 4 
J/cm2 or 8 J/cm2, promotes osteoblast and fibroblast proliferation, as well 
as increased collagen synthesis by epithelial cells. In addition, 810 nm 
light treatment with fluences of 5 J/cm2 and 25 J/cm2 was an effective 
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regimen for decreasing inflammatory cytokine levels in human rheumatoid 
arthritis synoviocytes (Yamaura et al., 2009). Treatment with 780 nm light 
was also effective in decreasing levels of inflammatory mononuclear cells 
and exudate in the inflamed area, while increasing the presence of 
chondrocytes and lubrication of the synovial joints of Wistar rats with 
collagen-induced arthritis (Alves et al., 2013). Da Rosa et al. (2012) 
compared the effects of 660 nm and 808 nm light in a rat model of 
osteoarthritis, using a fluence of 142 J/cm2, and it was shown that light 
therapy using 808 nm light was more successful than 660 nm light in 
stimulating angiogenesis and reducing fibrosis and exudate. Lastly, 
Castano et al. (2007) showed that treatment with 810 nm light reduced 
inflammation in zymosan-induced arthritis in rats. These studies indicate 
the therapeutic potential of PBM in joint-related inflammation. 
 
4. Effect of Photobiomodulation on Pro-Inflammatory Cytokines 
As the mechanisms for PBM are still not established, it is unclear how 
FR/NIR light absorption leads to cytokine regulation and reduction in 
inflammation. It has been found that NO production is associated with 
regulation of a variety of both pro-inflammatory and anti-inflammatory 
cytokines, including IL-1, IL-6, IL-8, IL-10, IL-12, interleukin-18, IFN-γ, and 
TNF-α (Prindeze et al., 2012). Umansky et al. (1998) demonstrated that 
NO concentration dictates whether the presence of NO will exert a pro-
inflammatory or anti-inflammatory effect in cells. It was found that when a 
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low concentration of the NO-generating compound glycerol trinitrate was 
added to endothelial cells, NF-κB activation was increased. In contrast, 
Muili et al. (2013) showed that low NO production was associated with 
anti-inflammatory effects of light treatment. When treating myelin 
oligodendrocyte glycoprotein-induced experimental autoimmune 
encephalitis (EAE) with 670 nm light in C57BL/6 mice, a reduction in NO 
production was observed (Muili et al., 2013). Treatment with 670 nm light 
was efficient in ameliorating inflammation in EAE in the presence of 
inducible nitric oxide synthase (iNOS), but had no effect in iNOS-deficient 
mice (Muili et al., 2013). Collectively, these studies suggest that the 
concentration of NO dictates whether its presence exerts a pro-
inflammatory of anti-inflammatory effect.     
 
Indeed, various studies have demonstrated the anti-inflammatory effects 
of PBM by reduction of pro-inflammatory mediators in various types of 
disorders. Pires et al. (2011) found that PBM via 780 nm light decreased 
the mRNA expression of IL-6, TGF-β, and the pro-inflammatory mediator 
cyclooxygenase-2 but not IL-1β, in both acute and chronic phases of 
tendinopathy in rats (Pires et al., 2011). Albertini et al.’s (2008) study 
supported the suppressive effect PBM exerts on TNF-α and IL-6 by 
demonstrating a reduction in these cytokines’ mRNA expression. They 
also showed that IL-1β mRNA expression in carrageenan-induced 
inflammation in rat paws was downregulated after treatment with 660 nm 
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and 684 nm light (Albertini et al., 2008). Finally, Muili et al. (2012) showed 
that treatment with 670 nm LED light led to a downregulation of IFN-γ and 
TNF-α in mice with autoimmune encephalomyelitis. These studies 
demonstrate the ability of NIR light to reduce pro-inflammatory cytokine 
levels.  
 
III. Hypothesis and Specific Aims 
Since it has been found that some Lyme arthritis patients experience 
persistent inflammatory symptoms even after a course of antibiotics, an 
additional form of therapy would be beneficial to alleviate their symptoms. 
The production of IL-17 and IFN-γ during the course of Lyme arthritis may 
contribute to ongoing joint inflammation. Therapy which decreases the 
levels of these cytokines may reduce inflammation and ease symptoms in 
Lyme arthritis patients. Since FR/NIR light therapy was found to have a 
therapeutic effect in other inflammatory disorders, including various types 
of arthritis, it is hypothesized that FR/NIR light therapy will also ameliorate 
joint inflammation in Lyme arthritis.  
 
The objective of this thesis is to determine the effects of 670 nm and 830 
nm red or NIR light on pro-inflammatory cytokine levels in Lyme arthritis. 
The hypothesis for this thesis is that PBM using 670 nm or 830 nm light 
will decrease inflammation in Lyme arthritis. This hypothesis was tested 
using two specific aims:  
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1. Determine the effect that 670 nm light and 830 nm light has 
on paw swelling and pro-inflammatory cytokine levels in B. 
burgdorferi-infected mice. The working hypothesis for this aim 
is that 670 nm and 830 nm light will ameliorate swelling and 
reduce IL-17 and INF-γ production in B. burgdorferi-infected 
mice. 
 
2. Determine the effect of 670 nm and 830 nm light on 
production of borreliacidal antibodies in infected mice. The 
working hypothesis for this aim is neither 670 nm nor 830 nm 
light will affect borreliacidal antibody production in B. 
burgdorferi-infected mice. 
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CHAPTER 2: MATERIALS AND METHODS 
 
I. Mice  
Six-to-12-week old, male and female C57BL/6 wild-type and IL-10-knock-
out (KO) mice, weighing 20-30 g, were used in this study. Mice were 
housed at the University of Wisconsin-Milwaukee animal facility in a 
humidity-controlled environment, with light and dark cycles of 12 hours 
each, at a room temperature of 21°C and were provided food and water 
ad libitum. Laboratory protocols were approved by the University of 
Wisconsin-Milwaukee Institutional Animal Care and Use Committee. 
  
II. Infection of Mice with B. burgdorferi 
B. burgdorferi strain 297 organisms were obtained from S. M. Callister 
(Gundersen Medical Center, La Crosse, WI) and stored at -80°C until use.  
Spirochetes were grown in Barbour-Stoenner-Kelly (BSK) medium at 34°C 
until a concentration of 2x107 organisms/mL was reached.  Viability was 
confirmed by darkfield microscopy. 
 
Wild-type and IL-10 KO mice (four to six per group) were injected 
subcutaneously in the hind paws with 106 viable B. burgdorferi strain 297 
organisms in 0.05 mL Barbour-Stoenner-Kelly (BSK) medium. Uninfected 
control mice were not used, due to a limited availability of experimental 
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animals and because the focus of this work is assessing efficacy of light 
therapy following infection. 
 
III. Light Treatment 
 
Groups of B. burgdorferi-infected wild-type and IL-10 KO mice received no 
light treatment or light treatment. 670 nm light treatment was administered 
with a Gallium/Aluminum/Arsenide (GaAlA) LED and consisted of 
illumination for 180 seconds at an intensity of 25 mW/cm2, resulting in a 
fluence/dose of 4.5 J/cm2. For 670 nm light treatment, mice were placed in 
a plexiglass box, which was positioned above the 670 nm array. Light 
treatment with 830 nm was administered with a hand-held WARP-10 LED 
device, and consisted of illumination for 90 seconds at an intensity of 50 
mW/cm2, resulting in a fluence/dose of 4.5 J/cm2. For the 830nm light 
treatment, the WARP-10 device was placed in a manner in which the 
entire area of the paw was covered by the light. Untreated mice were 
handled in the same manner as light-treated mice, with the exception that 
they were not exposed to light. 
 
In this infection model, resolution of mouse paw swelling typically occurs 
approximately 20 days after infection, with a peak of swelling exhibited 
approximately 8 days after infection.  In one experiment, groups of four to 
six infected mice were untreated or received one course of daily 670 nm 
light treatment between days 8 and 14 after infection. These mice were 
euthanized by isoflurane inhalation followed by cervical dislocation on day 
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20 after infection. In another experiment, groups of four mice received one 
course of 670 nm or 830 nm light treatment daily between days 2 and 7 
after infection. These mice were euthanized by isoflurane inhalation 
followed by cervical dislocation on day 8 after infection.  
 
IV. Measurement of Hind Paw Swelling 
The width and thickness of swelling in the ankle joints of mice were 
measured with a digital caliper with a sensitivity of 0.01 mm. Baseline 
measurements of hind paws of all mice were obtained before infection 
with B. burgdorferi. Measurements were obtained every other day 
following the initiation of light treatment and were obtained immediately 
prior to the treatment course. The data are presented as the average paw 
size for the respective groups +/- standard error of the mean.  
 
V. Cell Culture and ELISA  
Spleens were harvested on day 8 after infection.  Single-cell, whole spleen 
suspensions were obtained by passing cells through a nylon mesh screen 
into cold RPMI 1640 medium supplemented with L-glutamine and 25 mM 
HEPES. 1x106 whole spleen cells were incubated with 1x105 B. 
burgdorferi strain 297 organisms at 37°C in 5% CO2 for 24, 48, and 72 
hours. Control cells were incubated without B. burgdorferi organisms. IL-
17 and IFN-γ levels in the supernatants were measured using eBioscience 
mouse IL-17A and IFN-gamma ELISA Ready-Set-Go! Kits, respectively. 
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Plates were read at 450 nm and values were expressed as optical 
densities. Standard curves were obtained and used to calculate pg/mL for 
both cytokines.  
 
VI. Borreliacidal Assay 
Sera were used to determine titers of borreliacidal antibodies. Blood was 
collected from anesthetized mice by intracardiac puncture, and sera were 
obtained by centrifugation of blood samples at 1000 rpm for 10 minutes. 
Equal volumes of serum were pooled from each mouse within a group. 
Sera samples were serially diluted with BSK and then heated at 56°C for 
30 minutes to inactivate complement components. Twenty microliters of 
guinea pig complement and 1x104 viable B. burgdorferi strain 297 
organisms were added to the heat-inactivated sera. Samples were 
incubated for 16 hours at 34°C. Control samples included complement 
and B. burgdorferi without serum, serum and B. burgdorferi without 
complement, and serum and complement without B. burgdorferi. After 
incubation, presence of motile spirochetes was visualized (20 fields) using 
dark-field microscopy. The reciprocal of the greatest dilution with no viable 
B. burgdorferi was considered the borreliacidal antibody titer.  
 
 
VII. Data Analysis 
 
Swelling data between untreated and light-treated groups were analyzed 
using Student’s T-test. Cytokine levels in the supernatants of cells 
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obtained from untreated and treated mice were analyzed using the Mann-
Whitney U Test. Alpha levels were set at 0.05 prior to the beginning of the 
experiments, and P values less than or equal to 0.05 considered 
significant. 
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CHAPTER 3: RESULTS 
I. Specific Aim 1: Determine the effect that 670 nm light and 830 nm 
light has on paw swelling and pro-inflammatory cytokine levels in B. 
burgdorferi-infected mice 
 
1. Effects of Phototherapy on Hind Paw Swelling 
Wild-type and IL-10 KO mice were infected with B. burgdorferi strain 297 
and then treated or untreated with 670 nm light daily between days 8 and 
14 after infection. Wild-type mice exhibited mild paw swelling after 
infection (Figure 1A). Treatment of infected wild-type mice with 670 nm 
light caused a slight, but insignificant, increase in hind paw swelling 
throughout the duration of treatment (Figure 1A). This difference 
approached statistical significance (P=0.06) at day 14, the final day of 
treatment. However, paw swelling of treated wild-type mice began to 
decline on the fifth day of treatment and continued to decline after 
treatment. By contrast, the paw swelling of untreated mice increased 
during this time, peaking at day 18 after infection. At this time point, the 
paw swelling of previously-treated mice was lower than that of untreated 
mice. However, this difference was not significant (P=0.09). 
Infected IL-10 KO mice exhibited much greater hind paw swelling than 
wild-type mice (Figure 1B). Swelling peaked at day 6 after infection and 
began to decline just before 670 nm light treatment began. 670 nm light-
treated mice exhibited less paw swelling than untreated mice during and 
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after treatment (Figure 1B). However, this reduction in swelling was not 
statistically significant. 
    
 
 
Because the results for the first study were not statistically significant, the 
effect of light was tested earlier during inflammation. Wild-type and IL-10 
KO mice were infected with B. burgdorferi, and then either untreated or 
treated with 670 nm or 830 nm light daily between days 2 and 7 after 
infection. As expected, infected IL-10 KO mice (Figures 2B and 3B) 
exhibited greater paw swelling than their wild-type counterparts (Figures 
2A and 3A). 
Figure 1: Average change in paw swelling after B. burgdorferi strain 297 
infection of wild-type C57BL/6 mice (A; n=4 per group) and IL-10 KO 
mice (B; n=6 per group) treated with 670 nm light between days 8 and 14 
after infection. Untreated mice are denoted by empty squares and 
treated mice are represented by filled squares. Bars show standard 
error of the mean. 
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B. burgdorferi-infected wild-type mice exhibited mild hind paw swelling, 
and no changes in paw swelling were observed due to treatment of these 
mice with 670 nm light (Figure 2A). In addition, there were no significant 
differences between the paw swelling of 670 nm light-treated and 
untreated IL-10 KO mice infected with B. burgdorferi (Figure 2B). Both 
groups of IL-10 KO mice experienced a comparable decrease in paw 
swelling after the peak of inflammation. 
 
 
 
 
Similarly, in a different study, wild-type mice did not exhibit hind paw 
swelling after infection with B. burgdorferi, and swelling was not affected 
by treatment with 830 nm light (Figure 3A). In addition, treatment with 830 
Figure 2: Average change in paw swelling after B. burgdorferi strain 297 
infection of wild-type mice (A) or IL-10 KO mice (B) treated with 670 nm 
light between days 2 and 7 after infection. Untreated mice are denoted 
by empty squares and treated mice are represented by filled squares. 
n=4 in each group. Bars show standard error of the mean. 
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nm light did not cause significant changes in paw swelling of B. 
burgdorferi-infected IL-10 KO mice (Figure 3B). However, 830 nm light-
treated mice showed an overall increase in paw swelling by day 8 after 
infection, whereas untreated mice exhibited a decrease in paw swelling at 
that time (Figure 3B). However, this difference was not statistically 
significant.  
 
 
 
 
 
 
 
Figure 3: Average change in paw swelling after B. burgdorferi strain 297 
infection of wild-type mice (A) or IL-10 KO mice (B) treated with 830 nm light 
between days 2 and 7 after infection. Untreated mice are denoted by empty 
squares and treated mice are represented by filled squares. n=4 in each 
group. Bars show standard error of the mean. 
 
35 
 
 
2. Effects of Phototherapy on Inflammatory Cytokine Production 
On day 8 after infection, spleens were harvested from B. burgdorferi-
infected wild-type and IL-10 KO mice that were untreated or treated with 
670 nm or 830 nm light between days 2 and 7 after infection. 106 spleen 
cells were incubated with or without 105 B. burgdorferi for 24, 48, or 72 
hours. Supernatants were analyzed by ELISA for production of IL-17 and 
IFN-γ.  
 
i. Effects of 670 nm Light on Production of IL-17 
Treatment with 670 nm light did not affect the production of IL-17 from 
spleen cells of infected wild-type mice, regardless of whether the cells 
were unstimulated (Figure 4A) or stimulated with B. burgdorferi (Figure 
4B). However, in each case, the greatest amount of IL-17 production was 
observed among cells from treated mice after 48 hours of culture. In 
addition, IL-17 production by these cells was generally low (less than 60 
pg/ml supernatant), regardless of whether the cells were stimulated. 
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Similarly, treatment with 670 nm light did not significantly affect the 
production of IL-17 from cells of infected IL-10 KO mice, regardless of 
whether the cells were unstimulated (Figure 5A) or stimulated with B. 
burgdorferi (Figure 5B). A reduction in IL-17 production was observed 
after 24 hours of culture among stimulated cells of 670 nm light-treated IL-
10 KO mice (Figure 5B); however, this reduction was not statistically 
Figure 4: IL-17 production by unstimulated (A) or stimulated (B) 
spleen cells of B. burgdorferi-infected wild-type mice that were 
untreated or treated with 670 nm light.  n=4 in each group. In some 
cases, samples with equal values are shown as overlapping 
symbols. 
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significant. In general, cells from unstimulated mice tended to produce 
more IL-17 than cells from stimulated mice. 
 
 
 
ii. Effects of 670 nm Light on Production of IFN-γ 
Treatment with 670 nm light did not have a significant effect on IFN-γ 
production by unstimulated or stimulated cells of B. burgdorferi-infected 
wild-type mice (Figure 6A and Figure 6B). However, in general, cells from 
untreated mice exhibited more IFN-γ production than cells from treated 
Figure 5: IL-17 production by unstimulated (A) or stimulated (B) cells of B. 
burgdorferi-infected IL-10 KO mice that were untreated (n=4) or treated 
with 670 nm light (n=3). In some cases, samples with equal values are 
shown as overlapping symbols. 
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mice after 24 hours of culture. No IFN-γ production was detected from 
cultures of unstimulated or stimulated cells at 72 hours of incubation.  
 
 
 
 
However, we observed a significant reduction in IFN-γ production of cells 
from B. burgdorferi-infected, 670 nm light-treated, IL-10 KO mice. This 
significant reduction was observed after 24 hours of culture of both 
unstimulated (Figure 7A) and stimulated (Figure 7B) cells. Treatment of 
mice with 670 nm light also caused an overall reduction in IFN-γ 
Figure 6: IFN-γ production by unstimulated (A) or stimulated (B) cells of B. 
burgdorferi-infected wild-type mice that were untreated or treated with 670 nm 
light. n=4 in each group. In some cases, samples with equal values are shown 
as overlapping symbols. 
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production by unstimulated cells after 72 hours (Figure 7A). However, this 
reduction was not statistically significant. Overall, splenocytes of infected 
IL-10 KO mice (Figure 7) exhibited greater production of IFN-γ than 
infected wild-type mice (Figure 6), regardless of whether the mice were 
treated with 670 nm light. 
 
 
 
 
5. Effects of 830 nm Light on Production of IL-17 
 
Figure 7: IFN-γ production by unstimulated (A) or stimulated (B) cells of B. 
burgdorferi-infected IL-10 KO mice that were untreated (n=4) or treated with 
670 nm light (n=3). * denotes significant reduction compared to untreated 
mice (U = 0, p<0.05). Data points with a “glow” effect denote samples that 
possessed IFN-γ levels that exceeded the sensitivity of the assay. In some 
cases, samples with equal values are sh wn as overlapping symbols. 
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iii. Effects of 830 nm Light on Production of IL-17 
Treatment with 830 nm light did not significantly affect the production of IL-
17 by cells of B. burgdorferi-infected wild-type mice (Figure 8). An 
increase in IL-17 production was observed among unstimulated cells of 
830 nm light-treated mice after 72 hours of incubation (Figure 8A); 
however, these increases were not statistically significant. In addition, a 
similar increase was observed among stimulated cells of treated wild-type 
mice after 48 hours of incubation (Figure 8B). However, this increase also 
was not statistically significant.  
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Treatment of infected IL-10 KO mice with 830 nm light caused a significant 
increase in IL-17 production by unstimulated cells after 24 hours of 
incubation (Figure 9A). High levels of IL-17 production were observed 
among cells of both untreated and treated mice after longer incubation 
times. However, as multiple levels were higher than the sensitivity of the 
assay, no comparisons between these groups could be made. In addition, 
Figure 8: IL-17 production by unstimulated (A) or stimulated (B) cells of 
B. burgdorferi-infected wild-type mice that were untreated or treated with 
830 nm light. n=4 in each group. Data points with a “glow” effect denote 
samples that possessed IL-17 levels that exceeded the sensitivity of the 
assay. In some cases, samples with equal values are shown as 
overlapping symbols. 
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high levels of IL-17 were produced by stimulated cells of untreated and 
treated mice at all time points (Figure 9B). 
 
 
 
 
 
 
iv. Effects of 830 nm Light on Production of IFN-γ 
Treatment of infected wild-type mice with 830 nm light did not cause a 
significant effect on IFN-γ production (Figure 10). While an increase in IL-
17 production was observed among unstimulated cells of untreated mice 
Figure 9: IL-17 production by unstimulated (A) or stimulated (B) cells of B. 
burgdorferi-infected IL-10 KO mice that were untreated (n=3) or treated with 
830 nm light (n=4). * denotes significant increase compared to untreated 
mice (U = 0, p<0.05). Data points with a “glow” effect denote samples that 
possessed IL-17 levels that exceeded the sensitivity of the assay. In some 
cases, samples with equal values are shown as overlapping symbols. 
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after 72 hours, it was not statistically significant (Figure 10A). In general, 
higher levels of IFN-γ were produced by stimulated cells than unstimulated 
cells, from both untreated and treated mice (Figure 10B). However, as 
multiple readings of 24- and 72-hour cultures of stimulated cells were 
higher than the sensitivity of the assay, no comparisons between these 
groups could be made. There were no differences in IFN-γ production 
after 48 hours of incubation of stimulated cells from untreated and treated 
mice. 
 
 
 
 
Figure 10: IFN-γ production by unstimulated (A) or stimulated (B) cells of 
B. burgdorferi-infected wild-type mice that were untreated or treated with 
830 nm light. n=4 in each group. Data points with a “glow” effect denote 
samples that possessed IFN-γ levels that exceeded the sensitivity of the 
assay. In some cases, samples with equal values are shown as 
overlapping symbols. 
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We were able to make few claims about the effect of 830 nm light 
treatment on IFN-γ production of infected, IL-10 KO mice. While there was 
no difference in IFN-γ production by unstimulated cells after 24 hours of 
incubation (Figure 11A), multiple readings that exceeded the sensitivity of 
the assay for 48- and 72-hour cultures of unstimulated cells prevented a 
comparison. This was also the case for all cultures of stimulated cells 
obtained from 830 nm-light treated, IFN-γ mice (Figure 11B).  
 
 
  
  
Figure 11: IFN-γ production by unstimulated (A) or stimulated (B) cells of B. 
burgdorferi-infected IL-10 KO mice that were untreated (n=3) or treated with 
830 nm light (n=4). Data points with a “glow” effect denote samples that 
possessed IFN-γ levels that exceeded the sensitivity of the assay. In some 
cases, samples with equal values are shown as overlapping symbols. 
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II. Specific Aim 2: Determine the effect of 670 nm and 830 nm light on 
production of borreliacidal antibodies in infected mice 
1. Effects of Phototherapy on Borreliacidal Antibody Titers 
The effect of 670 nm and 830 nm light on borreliacidal antibody titers was 
determined. Sera were obtained on day 8 after infection of wild-type and 
IL-10 KO mice with B. burgdorferi. Mice were untreated or treated daily 
between days 2 and 7 after infection with either 670nm or 830nm light.  
 
It could not be determined whether treatment of B. burgdorferi-infected 
wild-type mice with 670 nm light affected borreliacidal antibody titers 
(Figure 12A). Both titers were high (≥40,960) and exceeded the level of 
detection of the assay. By contrast, borreliacidal antibody titers of infected 
IL-10 KO mice were notably lower. Untreated, infected IL-10 KO mice 
exhibited a borreliacidal antibody titer of 160. Treatment of infected IL-10 
KO mice with 670 nm light increased borreliacidal antibody titers to 20,480 
(Figure 12A). 
 
In another experiment, untreated B. burgdorferi-infected wild-type mice 
exhibited a borreliacidal antibody titer of 5120. By contrast, treatment of B. 
burgdorferi-infected wild-type mice with 830 nm light resulted in a higher 
borreliacidal antibody titer (≥40,960) (Figure 12B). In addition, untreated B. 
burgdorferi-infected, IL-10 KO mice exhibited a borreliacidal antibody titer 
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of 10,240. Treatment of infected IL-10 KO mice with 830 nm light reduced 
borreliacidal antibody titers to 2,560 (Figure 12B). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 12: Serum borreliacidal antibody titers of B. burgdorferi-
infected wild-type (black) and IL-10 KO (green) mice that were 
untreated (open bars) or treated (filled bars) with  670 nm light (A) or 
830 nm light (B). Sera were collected on day 8 after infection. WT, 
wild-type mice. 
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CHAPTER 4: DISCUSSION 
 
I. Introduction 
 
Lyme arthritis is a complication resulting from infection with the spirochete 
Borrelia burgdorferi. The incidence of Lyme disease has recently been 
shown to be ten times more common than previously thought (Centers for 
Disease Control and Prevention, 2013a). Although antibiotics are typically 
administered for treatment of the disease, 10% of treated Lyme arthritis 
patients still experience arthritis. Therefore, it would be beneficial to 
identify other forms of therapy for Lyme arthritis in the event that treatment 
with antibiotics is ineffective.  
 
PBM with light from far-red to near-infrared regions (630-900 nm) has 
been used to treat a wide variety of disorders, such as traumatic brain 
injury, retinal degeneration, and delayed wound healing (Whelan et al., 
2001; Eells et al., 2003; Muili et al., 2013), although the mechanism of 
action of PBM remains to be completely elucidated (Fitzgerald et al., 
2013). It is established that a photoacceptor must absorb photons to 
stimulate the biological processes of PBM (Karu, 1989). PBM has been 
found to be effective in reducing a number of pro-inflammatory mediators 
in various arthropathies (Castano et al., 2007; Yamaura et al., 2009; Hsieh 
et al., 2014). Since Lyme arthritis is known to be propagated by pro-
inflammatory cytokines, including IFN-γ and IL-17 (Yin et al., 1997; 
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Burchill et al., 2003), PBM may have potential therapeutic effects on the 
inflammation associated with disease. 
 
The purpose of this thesis was to determine the effects that 
photobiomodulation using 670 nm and 830 nm light had on the 
inflammatory state in Lyme arthritis, as well as on the borreliacidal 
antibody titers of infected mice. The hypothesis of this thesis was that 
PBM using 670 nm or 830 nm light will decrease inflammation in Lyme 
arthritis. This hypothesis was tested using two specific aims.  
 
II. Specific Aim 1: Determine the effect that 670 nm light and 830 nm 
light has on paw swelling and pro-inflammatory cytokine levels in B. 
burgdorferi-infected mice  
The working hypothesis of this specific aim was that 670 nm and 830 nm 
light will ameliorate swelling and reduce IL-17 and INF-γ production in B. 
burgdorferi-infected mice. To determine the effectiveness of 670 nm and 
830 nm light on alleviating inflammation, the paws of B. burgdorferi-
infected mice were measured, and IL-17 and IFN-γ levels were obtained 
from cultured spleen cells. This hypothesis was partially supported. While 
treatment with either wavelength of light did not significantly affect hind 
paw swelling of infected mice (Figures 1-3), IFN-γ production by spleen 
cells of infected IL-10 KO mice was significantly lower in 670 nm light-
treated mice than untreated controls (Figure 7). However, treatment with 
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830 nm light tended to increase IL-17 production by spleen cells of 
infected IL-10 KO mice (Figure 9).  
 
An initial experiment testing the effect of 670 nm light on murine Lyme 
arthritis was conducted by administering treatment starting near the peak 
of inflammation (day 8 after infection) for seven consecutive days. 
Although only one observation approached statistical significance (Figure 
1A), some patterns did emerge. Treatment of wild-type mice using 670 nm 
light did cause a slight (P=0.06) increase in paw swelling at day 14 after 
infection, the day treatment ended (Figure 1A). The swelling of treated 
mice gradually subsided, while the swelling of untreated mice exhibited a 
second increase. By day 18 after infection, the swelling of treated mice 
was slightly (P=0.09) less than that of untreated mice. In addition, 
treatment of infected IL-10 KO mice lowered swelling, although not 
significantly (Figure 1B).  It is possible that 670 nm light treatment had 
minimal effects on paw swelling because wild-type C57BL/6 mice develop 
mild swelling and minimal arthritis after infection with B. burgdorferi in the 
first place. In addition, the lack of significant effects in infected IL-10 KO 
mice could be due to treatment beginning too late. These mice exhibited a 
dramatic increase in paw swelling by day 6 after infection, with both 
treated and untreated groups showing a similar decline by day 10 after 
infection. It is possible that by this point, the inflammatory mediators may 
have exerted effects that light treatment could not alleviate. By day 8 after 
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infection with B. burgdorferi, IL-10 KO mice develop moderate 
inflammation of the perisynovial tissues of the ankle joint and the knee 
(Hansen et al., 2013). However, the degree of paw swelling in our IL-10 
KO mice was nearly double than that which our laboratory has previously 
observed (Hansen et al., 2013). The inflammation in these mice may have 
been too great to be affected by light therapy. It has been suggested by 
Karu (1989) that the rate of cellular proliferation and tissue regeneration 
must occur at a maximal rate for PBM to be effective. Thus, it is possible 
that treatment efficacy would be enhanced when maximal levels of 
regenerative factors are not reached and are not overwhelmed by the 
production of inflammatory mediators. 
 
To determine whether PBM administration would be more effective in 
reducing inflammation at an earlier course of disease, we assessed the 
effects of 670 nm light treatment starting on day 2 after infection. We also 
wanted to know whether 830 nm light could be efficient in reducing 
inflammation, since 830 nm light has a greater ability to penetrate tissue 
than 630 nm light (Giacci et al., 2014) and it demonstrates therapeutic 
effects in some systems (Freitas et al., 2001; Stadler et al., 2001; Mendez 
et al., 2004). Our results showed that early treatment with 670 nm light did 
not significantly affect the paw swelling that resulted from B. burgdorferi 
infection (Figures 2A and 2B).  As expected, untreated, infected wild-type 
mice did not exhibit significant increases in paw swelling after infection 
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(Figure 2A). We also found that there were no significant differences in the 
changes in paw size between infected, treated IL-10 KO mice and their 
untreated counterparts. Both the treated and untreated groups saw 
resolution in paw swelling beginning after day 6 post-infection (Figure 2B). 
We observed that by day 8 after infection, 670 nm light-treated IL-10 KO 
mice exhibited slightly greater paw swelling than untreated mice. 
However, this change was not statistically significant.  
 
In another experiment, we treated infected mice with 830 nm light at this 
same, early time. Wild type mice again did not show any significant 
changes in paw sizes, whether they were untreated or treated (Figure 3A). 
There were also no statistically significant differences observed when B. 
burgdorferi-infected IL-10 KO mice were treated with 830 nm light. 
However, the untreated group exhibited a reduction in paw swelling 
beginning after day 6 after infection (Figure 3B), while the 830 nm light- 
treated group exhibited a continued increase in paw swelling at the same 
time. While the differences in swelling between untreated and treated mice 
at day 8 were not significant, it is possible that 830 nm light treatment of 
infected IL-10 KO mice may have either induced even greater paw 
swelling or delayed its onset.  
 
Some factors may account for why 670 nm light had little effect on paw 
swelling, while 830 nm light appeared to cause potentially more swelling. 
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The more penetrative nature of 830 nm light, compared to the 670 nm 
wavelength (Giacci et al., 2014), may be a reason why the 830 nm light 
treatment may have resulted in these trends. It is possible that this higher 
degree of penetration led to a greater production of inflammatory 
molecules, resulting in greater edema and paw swelling. For example, 830 
nm light treatment has been shown to increase NO production by 
fibroblast cells in a wound-healing study (Houreld et al., 2010). Since NO 
has been found to modulate NF-κB activity (Connelly et al., 2001), NO 
displacement by cytochrome c oxidase after light absorption may lead to 
NF-κB-induced transcription of pro-inflammatory mediators. These events 
could result in increased paw swelling after several days of 830 nm light 
treatment. Another potential reason for the different effects of 670 nm and 
830 nm light treatment is that longer wavelengths may induce different 
effects on cells than shorter wavelengths. For example, treatment with 675 
nm light induced maximum fibroblast proliferation, whereas 810 nm light 
treatment inhibited it (Moore et al., 2005). 830 nm light could potentially 
inhibit cellular proliferation, and could be a reason why 670 nm light had 
little to no effect on paw swelling, while mice treated with 830 nm light 
exhibited trends toward slightly increased swelling.  
 
The sacrifice of the mice at day 8 after infection prevented a more 
complete examination of paw swelling, as well as cytokine levels and 
borreliacidal antibody titers. This was due to an unavailability of a 
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sufficient number of animals. When 670 nm light was administered from 
day 8 to day 14 after infection, paw swelling was examined for an 
additional six days after treatment ended, and some differences in paw 
swelling between the light-treated and untreated wild type mice were 
observed (Figure 1A). Therefore, in a future study, mice will be observed 
for longer periods after this early light treatment regimen. 
 
To investigate the effects of PBM on pro-inflammatory cytokines in B. 
burgdorferi-infected mice, IL-17 and IFN-γ levels were measured. We 
found that 670 nm light had no significant effect on the production of IL-17 
from unstimulated (Figure 4A) or stimulated (Figure 4B) splenocytes of 
infected wild-type C57BL/6 mice. This was expected, as wild-type 
C57BL/6 mice only exhibit mild arthritis after infection. This is due, in part, 
to their ability to produce lower levels of pro-inflammatory cytokines and 
higher levels of anti-inflammatory cytokines, such as IL-10, than arthritis-
susceptible mice (Brown et al., 1999). In general, unstimulated cells from 
treated, infected wild-type mice appeared to produce more IL-17 than 
those from untreated mice after 48 hours of stimulation. However, these 
changes were not significant. It is possible that 670 nm light treatment was 
able to change the levels of IL-10, or other anti-inflammatory cytokines, 
such that there was an increasing pro-inflammatory microenvironment in 
vitro.  However, this is not supported by our paw swelling data (Figure 2A). 
54 
 
 
We will additionally measure the levels of anti-inflammatory mediators in a 
future study. 
 
IL-17 production by unstimulated spleen cells of infected IL-10 KO mice 
(Figure 5A) was, overall, greater than that of their wild-type counterparts 
(Figure 4A). This was expected, as C57BL/6 mice deficient in IL-10 
develop greater inflammation than wild type mice (Brown et al., 1999). 
These results also support recent findings that a lack of IL-10 in these 
infected mice is associated with a higher production of IL-17 (Hansen et 
al., 2013). Stimulated spleen cells of 670 nm light-treated, infected IL-10 
KO mice showed a reduction (albeit insignificant) of IL-17 after 24 hours of 
incubation (Figure 5B). Although these results did not reach statistical 
significance, they suggest that 670 nm light treatment may disrupt IL-17 
production, despite conditions in which inflammation is generally favored.  
However, IL-17 production was notably less in stimulated cultures than in 
unstimulated cultures (Figure 5). Our laboratory has recently shown that 
stimulation of cells with B. burgdorferi can cause an immediate decrease 
in IL-17 production, and that this decrease can occur independently of IL-
10 (Hansen et al., 2013). This suggests that anti-inflammatory mediators 
other than IL-10 may be affecting this reduction in IL-17, and that these 
factors may be upregulated by 670 nm light. 
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We also found that 670 nm light treatment did not significantly affect IFN-γ 
production by the spleen cells of infected wild-type mice, regardless of 
whether the cells were unstimulated or stimulated (Figure 6A and Figure 
6B). However, we did observe that cells of treated mice produced less 
IFN-γ overall after 24 hours, although these results were not statistically 
significant. In addition, we found that infected IL-10 KO mice produced 
greater levels of IFN-γ (Figure 7) than their wild-type counterparts (Figure 
6). This would also be attributed to the absence of IL-10 in these mice, 
which have a reduced ability to inhibit inflammatory mediators such as 
IFN-γ (Gazzinelli et al., 1996). Importantly, we found that cells of 670 nm-
treated IL-10 KO mice produced significantly less IFN-γ than cells from 
untreated mice, regardless of whether the cells were unstimulated or 
stimulated, after 24 hours of incubation (Figure 7A and Figure 7B). We 
observed a similar, although insignificant, trend among unstimulated cells 
after 72 hours of incubation. Collectively, this suggests that 670 nm light 
treatment could reduce inflammatory cytokine production in this system. 
This was more clearly seen among cells of IL-10 KO mice, which exhibit 
clear inflammation and develop arthritis after B. burgdorferi infection 
(Hansen et al., 2013). 
 
The effects of 670 nm light on IL-17 and IFN-γ levels were not consistent 
with our results of paw swelling. While 670 nm light treatment did not 
reduce paw swelling in infected IL-10 KO mice, it did significantly reduce 
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IFN-γ production. It is possible that inflammation may still occur even with 
relatively lower production of inflammatory cytokines, especially in the 
mice that lack IL-10. Histopathologic examination of the paws would be 
required to determine whether the differences in cytokine production are 
consistent with structural changes. Blocking IL-17 (Hansen et al., 2013) or 
IFN-γ (Sonderegger et al., 2012) reduced the severity of arthritis in B. 
burgdorferi-infected, IL-10 KO mice. Therefore, it is possible that the 
reduction in inflammatory cytokine production we observed among 670 nm 
light-treated mice may be sufficient to reduce pathology, if not edema  
 
Treatment of infected wild-type mice with 830 nm light did not induce 
significant changes in the production of IL-17 by either unstimulated or 
stimulated cells (Figure 8A and Figure 8B). However, in general, cells from 
these treated wild-type mice produced greater levels of IL-17 levels than 
their untreated counterparts, regardless of whether the cells were 
unstimulated or stimulated. These increases were observed among 
unstimulated cells after 48 and 72 hours of incubation (Figure 8A) and 
among stimulated cells after 24 and 48 hours of incubation (Figure 8B). 
Importantly, a significant increase in IL-17 production was observed 
among unstimulated cells of treated IL-10 KO mice after 24 hours of 
incubation (Figure 9A). These results suggest that treatment with 830 nm 
light stimulates the IL-17 response, rather than alleviating it, in B. 
burgdorferi-infected mice. Based on the general increase of IL-17 
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production observed among cells of treated wild-type mice (Figure 8), it is 
not surprising that IL-10 KO mice would exhibit even higher IL-17 levels 
(Figure 9) and, in one case, a significant increase in its production (Figure 
9A). It was surprising that 830 nm light treatment resulted in these 
increases, even if most of these increases were not statistically significant. 
However, the fact that most of these changes in IL-17 production were not 
significant is consistent with the lack of significant changes we observed in 
paw swelling (Figure 3). However, there was a trend towards increased 
swelling in infected IL-10 KO mice following 830 nm light treatment, which 
may be partially explained by the significant increases in IL-17 production 
(Figure 9A). 
 
Similarly, 830 nm light treatment did not significantly affect IFN-γ 
production by cells of either wild type or IL-10 KO mice (Figure 10). 
However, unstimulated cells of 830 nm light-treated, infected wild-type 
mice exhibited a trend toward increased IFN-γ production after 72 hours of 
incubation (Figure 10A). We are unable to determine the effect of 830 nm 
light treatment on IFN-γ production among cells of infected IL-10 KO mice, 
as many of these values exceeded the sensitivity of the assay (Figures 
11A and 11B).  
 
Collectively, these results suggest that 830 nm light treatment may 
actually induce pro-inflammatory cytokine production and possibly cause 
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increased inflammation, especially in mice lacking IL-10. B. burgdorferi-
infected IL-10 KO mice have been considered to be a model of 
dysregulated Lyme arthritis (Sonderegger et al. 2012), which may reflect 
the mechanism of disease in many people. Thus, 830 nm light treatment 
may exacerbate these effects, should this treatment regimen be used on 
Lyme arthritis patients. As with 670 nm light treatment, whether 830 nm 
light treatment has any clinical effect would require histopathological 
examination of the paws. In addition, a transfer study using the spleen cell 
supernatants of the 830 nm light-treated IL-10 KO mice could further 
determine whether the increase in IL-17 production contributes to a pro-
inflammatory environment in paw inflammation. 
 
Varying the parameters of light treatment may increase effectiveness in 
future studies. It is possible that the 830 nm light treatment induced 
increases in paw swelling (albeit insignificantly), increased IL-17 
production, and failed to reduce IFN-γ levels due to a  higher intensity or 
shorter treatment time than what could have been effective for this Lyme 
arthritis mouse model. While the use of 670 nm and 830 nm lights both 
utilized a total fluence of 4.5 J/cm2, the treatment times and intensity used 
for each were different. 670 nm light was applied for 180 seconds, with an 
intensity of 25 mW, while 830 nm light was applied for 90 seconds with an 
intensity of 50 mW. Since duration of treatment is inversely related to 
intensity, changing one of these parameters would inevitably change the 
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other. Irradiation time was shown to be an important factor in the 
effectiveness of PBM, regardless of fluence or intensity (Castano et al., 
2007). Therefore, treatment time with 830 nm light could be increased in 
future studies.  
 
A major question is how PBM can have such varying effects, as seen in 
this, and other, studies. A possible explanation for this is based on the 
phenomenon of hormesis, in which molecules that are typically considered 
harmful in high amounts could induce a helpful response at lower dosages 
(Mattson, 2008). In the context of PBM, light effectiveness is based on the 
biphasic dose response, which reflects hormesis. In cases which PBM 
was effective or did not cause damage, factors that are typically 
associated with an increase in inflammation, such as NO, reactive oxygen 
species (ROS), and NF-κB induction, may be immunoprotective, 
depending on the their concentrations. The 830 nm light may have 
triggered a higher production of NO, ROS, and other pro-inflammatory 
mediators than the 670 nm light, resulting in anti-therapeutic results. On 
the other hand, 670 nm light may have triggered a more “optimal” level of 
NO than the 830 nm treatment, which, in turn, causes cells to produce 
more cytoprotective factors that increase cellular protection. In this sense, 
it is possible that the 670 nm light triggers an amount of NO that is too 
small to cause damage, so that negligible damage is seen.  
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III. Specific Aim 2: Determine the effect of 670 nm and 830 nm light 
on B. burgdorferi retention in infected mice 
The working hypothesis for this specific aim was that neither 670 nm nor 
830 nm light would affect borreliacidal antibody production in B. 
burgdorferi-infected mice. To test this hypothesis, borreliacidal antibody 
titers were determined for both untreated, infected mice and infected mice 
treated with either 670 nm or 830 nm light. Our hypothesis was not 
supported. We saw that light treatment with either wavelength induced 
changes in borreliacidal antibody titers in both infected wild-type and IL-10 
KO mice. This was surprising, since we did not expect systemic anti-
pathogen changes to occur with this therapy. However, the effects of 670 
nm and 830 nm light treatment support our observations of cytokine 
production, particularly in IL-10 KO mice.  
 
We could not determine whether treatment with 670 nm light induced 
changes in borreliacidal titers in infected wild-type mice, as both groups 
exhibited high titers (≥40,960) that exceeded the detection level of the 
assay (Figure 12A). However, significant differences were observed in the 
borreliacidal antibody titers between untreated and 670 nm light-treated, 
infected IL-10 KO mice (Figure 12A). Untreated, infected IL-10 KO mice 
possessed a low borreliacidal antibody titer (160), indicating a reduced 
ability to eradicate the spirochete. In contrast, 670 nm light-treated, 
infected IL-10 KO mice possessed a considerably higher borreliacidal 
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antibody titer of 20,480. These results suggest that treatment with 670 nm 
light may have increased the ability of infected IL-10 KO mice to eliminate 
the spirochete. This is consistent with the reduced levels of inflammatory 
cytokine production, especially that of IFN-γ (Figures 6 and 7), observed 
with treatment at this wavelength.  
 
In another experiment, untreated, infected wild-type mice exhibited a 
borreliacidal antibody titer of 5120. This was significantly lower than that of 
our study using 670 nm light. Treatment of infected wild-type mice with 
830 nm light resulted in a higher borreliacidal antibody titer, with levels 
exceeding that which were detectable by the assay (≥40,960) (Figure 
12B). By contrast, untreated, infected IL-10 KO mice possessed a 
borreliacidal antibody titer of 10,240. This also was significantly higher 
than that of our study using 670 nm light. However, treatment of infected 
IL-10 KO mice with 830 nm light reduced the borreliacidal antibody titer to 
2560, suggesting that 830 nm light treatment reduced the ability of 
infected IL-10 KO mice to eliminate B. burgdorferi. This is consistent with 
the trends toward increased inflammatory cytokine production, especially 
that of IL-17 (Figures 8 and 9), that we observed in 830 nm light-treated 
mice. 
 
IL-10 is a known regulator of B cell differentiation and antibody production 
(Rousset et al., 1992), so the low borreliacidal antibody titer exhibited by 
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untreated IL-10 KO mice was not surprising. However, it is interesting that 
670 nm light treatment was capable of increasing the borreliacidal 
antibody titer of infected IL-10 KO mice. These results suggest that 670 
nm light treatment was capable of inducing B cell antibody production via 
other mediators. IL-21 has been shown to play a role in the differentiation 
of B cells (Bryant et al., 2007). Therefore, 670 nm light may have 
increased the levels of IL-21, as well. However, IL-21 is a known Th17 
cytokine, and the Th17 (IL-17) response was not increased in these mice. 
Alternatively, the increase in borreliacidal capability of the 670 nm treated 
IL-10 KO mice may have been due to the decrease in IFN-γ production of 
these mice. Recombinant IFN-γ has been demonstrated to decrease the 
borreliacidal antibody production by lymph node cells, while also 
decreasing the number of B cells of B. burgdorferi-infected C3H mice 
(Munson et al., 2002).   
 
By contrast, 830 nm light treatment reduced borreliacidal antibody titers in 
IL-10 KO mice, indicating that B cell differentiation and/or antibody 
production may have been reduced after treatment. However, it is possible 
that the increase in borreliacidal antibody production in 830 nm light-
treated wild type mice may be due to an increase in IL-21, as these mice 
exhibited trends toward increased IL-17 production (Figure 8). It is likely 
that light treatment affected additional B cell-associated cytokines, as well. 
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Chapter 5: Conclusions and Future Directions 
 
The purpose of this thesis was to determine whether photobiomodulation 
using either 670 nm light or 830 nm light would help alleviate inflammation 
in murine Lyme arthritis. The central hypothesis for this study was that 
PBM using 670 nm or 830 nm light will decrease inflammation in Lyme 
arthritis. Two specific aims were pursued to test this hypothesis. The first 
aim was to determine the effect that 670 nm light and 830 nm light has on 
paw swelling and pro-inflammatory cytokine levels in B. burgdorferi-
infected mice. The working hypothesis for this specific aim was that 670 
nm and 830 nm light will ameliorate swelling and reduce IL-17 and IFN-γ 
production in B. burgdorferi-infected mice. The second aim was to 
determine the effect of 670 nm and 830 nm light on production of 
borreliacidal antibodies in infected mice. The working hypothesis for this 
specific aim was that neither 670 nm nor 830 nm light will affect 
borreliacidal antibody production in B. burgdorferi-infected mice. 
 
Our hypothesis was partially supported, in that PBM using 670 nm light 
was capable of significantly decreasing IFN-γ production. However, it was 
unable to decrease the paw swelling exhibited in murine Lyme arthritis, 
and, surprisingly, it  increased the borreliacidal antibody titer in a model of 
dysregulated disease. In addition, our hypothesis was not supported by 
the use of 830 nm light. Treatment with 830 nm light did not significantly 
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affect paw swelling, it significantly increased IL-17 production, it and 
reduced borreliacidal antibody titers in the model of dysregulated Lyme 
arthritis. Our results indicate that different wavelengths may possess 
varying effects on inflammation in Lyme arthritis. Histopathologic analysis 
of these paws is required to determine the most relevant effects of these 
treatments.  
 
The timing of treatment administration is critical for the success of PBM.  A 
potential reason for the lack of significant effects of PBM in this study is 
that the “optimal” degree of inflammation has not been inflicted in the 
mice. While an underlying principle of how photobiomodulation works is 
that tissue must be damaged in order for it to be repaired by red or NIR 
light, it is unknown to what degree the tissue must be damaged. It would 
be reasonable to hypothesize that cells cannot be too damaged, to the 
point in which the light cannot induce protective factors to repair the 
damage. It is possible that too early of a treatment may not be effective, 
as there may not be enough regenerative mediators involved in tissue 
repair to promote adequate regeneration at the time of LED application. In 
addition, the severe inflammation in our infected IL-10 KO mice may have 
prevented any noticeable change in swelling to occur.  Also, our study 
used extremely small sample sizes. Naturally, wide variations among the 
data could be expected in this system. In cases in which significant 
cytokine changes were observed, all of the values of one group were 
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higher than all of the values of the other group. In some cases, all of the 
values of one group were higher than all but one of those in the other 
group, which resulted in statistically insignificant results. A larger sample 
size is needed in future studies. 
 
Following this experiment, one of the next steps would be to investigate 
the histopathologic changes in the paws after light treatment to determine 
the severity of arthritis. This would also provide a clearer indication of the 
tissue or cellular changes by light treatment. It would also be beneficial to 
determine the time point at which peak levels of particular growth factors, 
collagen, osteoblasts, and synoviocytes are present, and start treatment 
then to determine whether PBM has any therapeutic effects. Treatment 
could also begin on days of peak growth factor and cellular generation 
rates. Doing so could enhance the effects of these mediators and 
potentially significantly decrease inflammation and increase regeneration 
of cells in the joints. 
 
It is also possible that the particular time of day treatment was 
administered was ineffective for the treatment of disease. Effects of light 
vary depending on the circadian rhythm of experimental animals. For 
example, treatment of neural inflammation in an EAE mouse model of 
multiple sclerosis showed that 670 nm light loses clinical effect when 
administered in the afternoon (J. Lyons, personal communication). In this 
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thesis, light treatment was given in the afternoon. As mice are nocturnal 
animals, 670 nm light treatment may be more effective if the light was 
applied in the evening, at a time when metabolic rates of mice were 
higher. Similarly, 830 nm light treatment may exert an anti-inflammatory 
effect in IL-10 KO mice if treatment had been given during the evening. 
Future studies should test this hypothesis by administrating 670 nm or 830 
nm at a later time of day in B. burgdorferi-infected mice. 
 
In addition, the effect 670 nm light may have on inducers and products of 
IL-17 activity should be investigated. IL-17 has been found to trigger the 
generation of IL-6 in the synoviocytes of rheumatoid arthritis patients 
(Chabaud et al., 1999), indicating a possible positive feedback loop 
between IL-17 and IL-6. Nardelli et al. (2008b) demonstrated that Borrelia- 
vaccinated and-infected mice administered both anti-IL-6 and anti-TGF-β 
antibodies exhibited a significant decrease in the severity of joint 
pathology, showing that both cytokines play a role in joint inflammation. 
Since Th17 cell differentiation is induced by IL-6 and TGF-β (Veldhoen et 
al., 2006), the levels of these two cytokines could also be affected by 
PBM. Investigating whether PBM has any effect on these cytokines, and 
whether these levels are consistent with  that of IL-17, would lend greater 
information about its effect on IL-17.  
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Our results showed that infected IL-10 KO mice treated with 670 nm light 
produced less IL-17 and IFN-γ and higher borreliacidal antibody titers than 
untreated mice. Since IL-10 is required for the attenuation of IL-17-
induced inflammation in murine Lyme arthritis (Hansen et al., 2013), as 
well as IFN-γ-mediated inflammation in general (Fiorentino et al., 1989), 
understanding the effects PBM may have on IL-10, specifically, would be 
necessary. This is particularly important, as we observed increases in 
inflammatory cytokines following treatment of infected IL-10 KO mice with 
830 nm light. 
 
In conclusion, we showed that treatment with 670 nm light resulted in 
general reductions of inflammation in the IL-10 KO mouse model of 
dysregulated Lyme arthritis. By contrast, treatment with 830 nm light 
resulted in general increases in inflammation in these mice. Additional 
studies are required to further define the effects of photobiomodulation on 
the symptoms of Lyme arthritis.  
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